The global asthma and COPD market is currently worth around US$20 billion. The top twelve pharmaceutical products by value had combined global sales of US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion. Combined sales of the top ten products were 21.1% higher than in 2004.

A number of older therapies, for asthma in particular, are widely available generically and there is fierce competition in the market. The asthma market accounts for the majority of the total and is valued at around US$15 billion. The COPD market is currently valued at US$4 - US$5 billion and is set to double in the next five years.

Future market growth will be driven by increasing disease awareness, an increasing patient pool, both in the paediatric asthma sector and the ageing population susceptible to COPD, and the launch of newer, more expensive therapies targeting areas of high unmet clinical need. These will be offset to some extent by the launch of new generics and the sales erosion of monotherapies by combination products.

Providing…
Product/Market Forecast by value 2006/2011 for current and future therapies
15 key products assessed
Market Context
Competitive Evaluation
Research Reviews

Covering…
Beta-2 Agonists
Inhaled Corticosteroids
Combination Therapies
Leukotrine Receptor Antagonists
Anti-Immunoglobulin E Therapy
Muscarinic Antagonists/ Anticholinergics
PDE-IV Inhibitors

About the Author
The report has been researched and written by Espicom staff analyst Karen Holmes. Karen has over 10 years market analysis experience in both medical devices and pharmaceuticals. She was the founding editor of Espicom's leading market analysis service, World Pharmaceutical Markets (WPM) and continues to contribute to both WPM and Medistat. Among her recent studies are Cardiovascular Drug Discoveries: What the future holds, Injectable Generic Drugs: Prospects and Opportunities to 2010 and The Indian Pharmaceutical Market. A rapidly expanding sector

An estimated 300 million people around the world have asthma and the European Federation of Allergy and Airway Diseases Patients Association have indicated that this could increase to 400-450 million by 2025. Around 30 million people in Europe have asthma, six million of whom have severe symptoms and around 1.5 million live in fear of dying from an attack.

COPD is one of the top five causes of disability and death in industrial societies. According to the WHO, COPD is the fourth leading cause of death worldwide, based on 2004 data. In the US, COPD is projected to be the third leading cause of death by 2020.

Results of the National Health Interview Survey in the US indicate that 12.1 million adults over the age of 25 reported being diagnosed with COPD in 2001. Of these, 9.2 million reported being diagnosed with chronic bronchitis, 2 million with emphysema and 0.9 million with both conditions. According to the National Heart, Blood and Lung Institute, this compares with around 24 million adults in the US who have evidence of impaired lung function, which suggests COPD is under-diagnosed.

According to the European Respiratory Society, the total cost of asthma in Europe is €17.7 billion per year (White Book, 2003). In the UK, around 5.2 million people are currently receiving treatment for asthma. Of these, 1.1 million are children, equivalent to one in ten. According to Asthma UK, asthma costs the NHS an average of £889 million per year.

Questions, Questions

What global revenue is Boehringer Ingelheim's novel COPD treatment Spiriva forecast to achieve in 2011?
What issue may effect the growth of Novartis/Genetech's Xolair in Europe?
What future revenues could be expected by AstraZeneca following the recent approval of Symbicort in the US?
To what degree will generic competition effect future revenues of GSK's market leading Seretide/Advair?
There are 29 compounds for Asthma and COPD in Phase I/II - what are they and who's developing them?

Current products evaluated and forecast to 2011 in the report

Xopenex
levalbuterol, Sepracor

Flixotide/Flovent
fluticasone propionate, GSK

Pulmicort
budesonide, AstraZeneca

Asmanex
mometasone furoate, GSK

Alvesco
ciclesonide+formoterol, Altana

Spiriva
tiotropium, Boehringer Ingelheim

Seretide/Advair
fluticasone+salmeterol, GSK

Symbicort
budesonide+formoterol, AstraZeneca

Singulair
montelukast, Merck

Xolair
omalizumab, Genentech/Novartis

Future products evaluated and forecast in the report

Ariflo
Clomilast, GSK

Daxas
roflumilast, Altana

Arformoterol
Sepracor

Indacaterol
Novartis

GSK 159797
GSK

NVA237
Novartis